phosphodiesterase 10a

N-Methylbenzamide is a potent inhibitor of phosphodiesterase 10A (PDE10A) with demonstrated anti-cancer activity.

PQ-10 (A-844337) is a PDE-10 inhibitor. PQ-10 induces brain glucose metabolism patterns, which may be a potential translational biomarker.

MT-3014 is a potent, highly selective, and brain-penetrant inhibitor of phosphodiesterase 10A (PDE 10A), with IC50 values of 0.062 nM for human PDE 10A and 0.09 nM for bovine PDE 10A.

AMG 579 is an efficacious and selective inhibitor of PDE10A (IC50 = 0.1 nM).

Mardepodect (PF-2545920) is a phosphodiesterase inhibitor selective for the PDE10A subtype with an IC50 of 0.37 nM and over 1000-fold selectivity over PDE. It is potentially useful for the treatment of schizophrenia. Phosphodiesterase 10A (PDE10A) is highly expressed in striatal medium spiny neurons of both the direct and indirect output pathways. Mardepodect can cross the blood-brain barrier.

5,7-Dichloropyrazolo[1,5-a]pyrimidine (fragment 5) is an inhibitor of the enzyme phosphodiesterase 10A (PDE10A) with a Ki value of 24 μM. This compound can be employed in research related to schizophrenia.

AMG-7980 is a highly specific phosphodiesterase 10A ligand. It shows a good uptake in the striatum.

JNJ-42259152 is a phosphodiesterase 10A PET tracer.

HPP-2 is a novel phosphodiesterase 10A (PDE10A) inhibitor used to treat schizophrenia.

THPP-4 inhibits phosphodiesterase 10A (PDE10A).

JNJ-42259152 F-18 can be used as a Novel Phosphodiesterase 10A PET Tracer.

ASP9436 Dihydrochloride is a potent, selective and orally active phosphodiesterase 10A inhibitor.

Gemlapodect (RO554965), a phosphodiesterase 10A (PDE10A) inhibitor, is utilized in schizophrenia research.

WAY-620445 is an active molecule [1]. It is a potent and selective inhibitor of phosphodiesterase 10A (PDE10A) with an IC50 of 1.8 nM. This compound has demonstrated efficacy in preclinical models of psychosis and is being explored as a potential therapeutic agent for schizophrenia.

Compound 8a (PDE10A-IN-3) serves as an inhibitor of phosphodiesterase 10A (PDE10A) and is utilized in schizophrenia research [1].

PDM-042 is a potent and selective orally active phosphodiesterase 10A (PDE10A) inhibitor, demonstrating strong inhibitory activities for human and rat PDE10A with IC50 values below 1 nM and over 1000-fold selectivity against other phosphodiesterases. PDM-042 can be used for schizophrenia research [1].